ADVANCE MPI 1: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to
thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. The
investigational drug, regadenoson (CVT-3146) is a selective A2A adenosine receptor agonist,
the receptor responsible for coronary vasodilation, and is being studied for potential use as
a pharmacologic stress agent in myocardial perfusion imaging (MPI) studies. This study will
compare the safety and efficacy of regadenoson to that of Adenoscan in detecting reversible
myocardial perfusion defects.